A new clinical trial will investigate whether a third dose of vaccine for people with weakened immune systems gives a stronger immune response than two doses.
The £2.2 million study will build on the OCTAVE trial, led by the University of Glasgow and co-ordinated by the University of Birmingham’s Cancer Research UK Clinical Trials Unit.
The results are expected later in 2021.